The identification of target organs and determining the adverse health effects have a key role in the development and risk/safety assessment of chemical entities and pharmaceuticals. This workshop is intended to benefit scientists in various discipline of drug development including sponsors, study directors, study monitor, pathologists, other scientists contributing to the toxicology studies, and regulatory authorities. The talks will cover current definitions and understanding of characterizing adversities in nonclinical toxicology studies as well as factors to be considered while determining the adverse nature of pathology findings in these studies. In the afternoon, the attendees will participate in an interactive case study session.

Presenter: Dr. Bhanu Singh BVSc, MS, DACVP, DABT, FIATP

Dr. Bhanu Singh is currently working as Scientific Director, Pathology at Nonclinical Safety in Janssen Pharmaceuticals, USA. In this role, Dr. Singh supports drug discovery and development by providing scientific leadership in the design and conduct of toxicology experiments that focus on characterization and safety of novel therapeutic targets and/or understanding potential mode of action for toxicity in preclinical studies. He also provides investigative guidance and scientific leadership in pathology to drug discovery teams and identify and lead collaborative mechanistic efforts with internal, external, consortia and academic investigators. He is a diplomate of American College of Veterinary Pathologist (DACVP) and American board of Toxicology (DABT). He is also a fellow of International Academy of Toxicologic pathology (IATP). Dr. Singh is actively involved in various professional activities for various Societies of Toxicologic Pathology like co‐chair for STP education course committee, Associate editor for Drug and Chemical Toxicology, Chair for IFSTP‐IATP webinar committee and chair for Dog INHAND committee.

Organizing Secretary: Dr. Satish Panchal, BVSc, MVSc, DIBTP, ERT